No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.

• Mabwell (Shanghai) Bioscience Co., Ltd.
• Yunnan Botanee Bio-Technology Group Co.LTD
• Genus plc
• Aurinia Pharmaceuticals Inc.
• Agios Pharmaceuticals, Inc.
• Ocular Therapeutix, Inc.
• Zenas BioPharma, Inc.
• Pell Bio-Med Technology Co., Ltd.